CHMP recommends four drugs in January
Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
by andreas lønstrup, translated by daniel pedersen
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started off 2023 by recommending US-based Bristol Myers Squibb’s Sotyktu (deucravacitinib) as a treatment for moderate-to-severe plaque psoriasis in adults.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
CHMP recommends expanded approval of Dupixent
For subscribers
Denmark rejects Janssen and Genmab drug twice in January
For subscribers
CHMP rounds off 2022 with five recommendations
For subscribers
.jpg&w=384&q=75)
